David Gauden

David is Chief Executive Officer of Blue Earth Therapeutics, where he leads the company’s mission to develop innovative radiopharmaceutical therapies for cancer patients. He led the creation of the company following its spin-out from Bracco in 2021. Previously, David co-founded Blue Earth Diagnostics and served as Chief Scientific Officer and later Chief Executive Officer, helping build the company from a start-up to a leader in nuclear medicine and molecular imaging before its acquisition by Bracco Imaging in 2019. He has more than 25 years of radiopharmaceutical industry experience.